Skip to search formSkip to main contentSkip to account menu

glucosyl-ifosfamide mustard

Known as: Beta-D-Glucosyl-Ifosfamide Mustard, Glufosfamide, glc-IPM 
A compound consisting of the mustard agent ifosforamide conjugated to glucose, with potential alkylating activity. Glufosfamide is cleaved by… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

Antineoplastic Agents, AlkylatingGlucoseIfosfamideProdrugs
D 19575

Narrower (1)

beta-D-glucosylisophosphoramide mustard

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
2009
2009
Possible contribution of beta-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells.
  • H. Arafa
  • European Journal of Pharmacology
  • 2009
  • Corpus ID: 33821749
Review
2008
Review
2008
Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.
BACKGROUND Cancer control by radiotherapy (RT) can be improved with concurrent chemotherapy. Outpatient strategies for sarcomas… 
Review
2005
Review
2005
Metabolism and Transport of Oxazaphosphorines and the Clinical Implications
The oxazaphosphorines including cyclophosphamide (CPA), ifosfamide (IFO), and trofosfamide represent an important group of… 
Review
2005
Review
2005
Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
2004
2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Review
2003
Review
2003
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
Highly Cited
2000
Highly Cited
2000
Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry.
Highly Cited
2000
Highly Cited
2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European…
PURPOSE To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of… 
Highly Cited
1998
Highly Cited
1998
Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.
For beta-D-glucosylisophosphoramide mustard (beta-D-Glc-IPM), a new alkylating drug in which isophosphoramide mustard is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)